Related Experiment Videos
Improving efficiency of ALS clinical trials using lead-in designs
1Research Institute CPMC, San Francisco, CA 94115, USA. moore@cooper.cpmc.or
Summary
New clinical trial designs for Amyotrophic Lateral Sclerosis (ALS) significantly reduce required sample sizes. These lead-in designs improve efficiency compared to standard parallel trials, potentially accelerating ALS drug development.
Area of Science:
- Clinical Trial Design
- Neurology
- Biostatistics
Background:
- Standard two-arm, parallel clinical trial designs are commonly used for Amyotrophic Lateral Sclerosis (ALS) research.
- These designs can be resource-intensive, requiring large sample sizes and long study durations.
Purpose of the Study:
- To introduce and evaluate novel, more efficient clinical trial designs for ALS.
- To demonstrate the statistical advantages of lead-in period designs over traditional parallel designs.
Main Methods:
- The proposed designs incorporate a patient-specific lead-in period before randomization to an intervention (drug or placebo).
- Efficacy is assessed by comparing the rate of change (slope) during the intervention period to the slope during the lead-in period within each patient.
- Sample size calculations were performed to quantify the efficiency gains.
Main Results:
- Lead-in designs demonstrated considerable efficiency improvements compared to standard parallel designs.
- A 4-month lead-in period in a 12-month ALS trial using the ALSFRS rate of decline reduced sample size by 44% compared to a parallel design.
- Variable lead-in periods offered even greater efficiency, with a potential sample size reduction of 70%.
Conclusions:
- Clinical trial designs incorporating a lead-in period offer a more efficient approach for ALS research.
- These designs can significantly reduce sample size requirements, potentially accelerating the evaluation of new ALS therapies.
- The findings support the adoption of lead-in designs for future ALS clinical trials.